# US 7,744,918 B2 · Drug-containing patch

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,918 B2
- Document ID: US7744918B2
- Status: Granted
- Kind: B2
- Application number: 11/284,357
- Filed: 2005-11-21
- Published: 2006-05-25
- Granted: 2010-06-29
- Earliest claimed: 2004-11-22
- Assignees: Hisamitsu Pharmaceutical Co., Inc.
- Inventors: Toshiro Yamaguchi; Mitsuru Kuribayashi
- Web page: https://patentgrep.com/patent/US7744918B2

## CPC

- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 9/7061: {Polyacrylates}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The problem of the invention is to provide a drug-containing patch which is very favorable in percutaneous absorbability and is excellent in sustainability of the drug efficacy, that is, the drug-containing patch having a sufficient percutaneous absorbability and effect sustainability in a degree to be actually used for therapy of patients. The problem is solved by a patch comprising a drug, a melting point lowering agent and an adhesive base.

## Claims

### Claim 1

A patch containing a drug selected from the group consisting of oxybutynin, fentanyl, pergolide, tandospirone, donepezil, tamsulosin, risperidone, flurazepam, butorphanol, perisoxal, pridinol, trihexyphenidyl, amantadine, tulobuterol, isoprenaline, propranolol, ketotifen, difenidol, morphine, meloxicam, valdecoxib and celecoxib, an adhesive base, at least one melting point lowering agent that lowers the melting point of the drug to increase skin permeation rate of the drug, wherein the melting point lowering agent is one or more selected from the group consisting of acetic acid, propionic acid, butyric acid, lactic acid, benzoic acid and salicylic acid, and a corresponding salt of the melting point lowering agent.

### Claim 2 (depends on 1)

The patch according to claim 1, wherein the melting point lowering agent lowers the melting point of the drug by 60° C. or more.

### Claim 3 (depends on 1)

The patch according to claim 1, wherein the melting point lowering agent is acetic acid and the corresponding salt is sodium acetate.

### Claim 4 (depends on 1)

The patch according to claim 1, wherein the adhesive base contains a styrene-isoprene-styrene block copolymer and/or an acrylate copolymer.

### Claim 5 (depends on 1)

The patch according to claim 1, wherein said patch contains one or more absorption enhancers selected from a group consisting of lauric acid diethanolamide, capric acid, isopropyl myristate and propylene glycol monolaurate.

### Claim 6 (depends on 1)

The patch according to claim 1 wherein the melting point lowering agent is in an amount of 0.5-5 mole against 1 mole of drug.

### Claim 7 (depends on 1)

The patch according to claim 1 wherein the amount of the melting point lowering agent is 1-3 moles against 1 mole of the drug.

### Claim 8 (depends on 1)

The patch according to claim 1, wherein the salt of the melting point lowering agent is in an amount of 0.5-5 mole against 1 mole of the drug.

### Claim 9 (depends on 8)

The patch according to claim 8, wherein the amount of the salt of the melting point lowering agent is 2-3 mole against 1 mole of drug.